“I think it’s really important that people keep signing up to these type of trials to push research forward.”
A trial comparing gemcitabine and docetaxel with doxorubicin for soft tissue sarcomas (GeDDiS)
This trial compared doxorubicin or a combination of docetaxel and gemcitabine as the first treatment for advanced soft tissue sarcoma. It was for people whose sarcoma had spread into the surrounding body tissue, or to other parts of the body.
The trial closed in 2014 and these results were published in 2017.
Cancer Research UK supported this trial.
More about this trial
- find out if this combination of drugs worked better than the standard treatment for soft tissue sarcoma that had spread
- learn more about the side effects
Summary of results
The trial team found that doxorubicin should remain as the standard first treatment for people with advanced soft tissue sarcoma.
- 129 people had doxorubicin
- 128 people had gemcitabine and docetaxel
- just under 73 ½ weeks for those who had doxorubicin
- just under 67 ½ weeks for those who had gemcitabine and docetaxel
- were 2 people in the doxorubicin group
- was no one in the gemcitabine and docetaxel group
- 23 people in the doxorubicin group
- 26 people in the gemcitabine and docetaxel group
- 60 people in the doxorubicin group
- 50 people in the gemcitabine and docetaxel group
- 25 people in the doxorubicin group
- 27 people in the gemcitabine and docetaxel group
- 19 in the doxorubicin group
- 26 in the gemcitabine and docetaxel group
- a drop in blood cells including a drop in white blood cells with a high temperature (febrile neutropenia)
- loss of hair
- tiredness (fatigue)
- feeling sick or being sick
- sore mouth
- loss of appetite
- diarrhoea or constipation
How to join a clinical trial
Dr Beatrice Seddon
Cancer Research UK
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer
University College London (UCL)
This is Cancer Research UK trial number CRUK/10/004.